April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
13 citations
,
August 1997 in “Steroids” Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
9 citations
,
August 2021 in “Biomedicines” 17β-estradiol boosts APE1/Ref-1 secretion in cells and mice via a calcium-dependent pathway.
105 citations
,
June 2010 in “The journal of sexual medicine” Testosterone undecanoate increases lean mass and causes various physical changes in female-to-male transsexuals.
May 2022 in “Reactions Weekly”
1 citations
,
July 2022 in “Journal of Drug Delivery Science and Technology” Niosomes and ethosomes can effectively carry the drug spironolactone, potentially improving treatment for hair loss and reducing side effects.
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Biochanin A is the safest herbal compound for potential hair loss treatment.
9 citations
,
October 1993 in “The Journal of Clinical Pharmacology” Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
May 1981 in “Inpharma (Balgowlah)” Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.
18 citations
,
May 2020 in “Biomolecules” Spironolactone, a heart and liver drug, has new uses including cancer treatment, viral infection prevention, and skin condition improvement.
11 citations
,
May 2010 in “Journal of Medicinal Chemistry” A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
164 citations
,
January 2003 in “Drugs”
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
January 2006 in “Benzina: Revista d'excepcions culturals” Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
January 2024 in “La Ciencia al Servicio de la Salud y Nutrición” Spironolactone is effective and safe for treating hair loss, excessive hair growth, and acne.
1 citations
,
September 2025 in “Archivio Italiano di Urologia e Andrologia” Serenoa repens extract, alone or with other supplements, improves urinary symptoms and lowers PSA levels.
19 citations
,
June 2010 in “Journal of acupuncture and meridian studies” A plant extract was found to effectively block an enzyme related to male hormone-related diseases.
1 citations
,
October 2002 in “The Journal of Urology”
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.